The combination of platelet count and lymphocyte to monocyte ratio is a prognostic factor in patients with resected breast cancer. Issue 18 (May 2020)

• Record Type: Journal Article
• Authors: Deng, Yunfu; Li, Wen; Liu, Xuejuan; Ma, Guangzhi; Wu, Qiang; Chen, Fang; Wang, Zhu; Zhou, Qinghua
• Other Names: Daoud. Sayed S. section editor.
• Is Part Of: Medicine. Volume 99:Issue 18(2020)
• Publication Date: 2020-05
• Subjects: breast cancer -- the combination of platelet count and lymphocyte-to-monocyte ratio -- prognosis; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000018755
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Many inflammation indicators have been reported to be related with patient outcomes in various cancers. Previous studies have evaluated the combination of platelet (PLT) and lymphocyte to monocyte ratio (COP-LMR) as a systemic inflammatory marker for prognostication in lung cancer, yet its prognostic role among breast cancer patients remains unclear. In the present study, a total of 409 breast cancer patients with surgical resection were retrospectively investigated. The receiver operating characteristic (ROC) curve was used to choose the optimal cut-off value of PLT and lymphocyte to monocyte ratio (LMR). Patients were classified into 3 groups according to the score of COP-LMR, and its relationship with various clinicopathological factors and breast cancer prognosis were further evaluated. The ROC curve analysis showed that COP-LMR had a higher area under the ROC curve for the prediction of 5-year disease-free survival and overall survival than PLT or LMR alone. Multivariable analysis showed that an elevated COP-LMR was an independent predictor of poor disease-free survival ( P = .032) and overall survival ( P = .005). Subgroup analysis revealed that COP-LMR was still significantly associated with prognosis in both luminal A and luminal B subtypes. Preoperative COP-LMR is a potential prognostic factor in breast cancer patients who underwent surgery.